Annual Review Course Bundle (2018)
In preparation for the American Board of Urology (ABU) Qualifying (Part 1) Examination, residents need to have basic urologic knowledge to prepare them for the ABU examinations. To fulfill this need, the American Urological Association (AUA) developed this course to disseminate current urologic knowledge. This course is also of interest to practicing urologist preparing for the Recertification Examination as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.
This extended learning option includes non-CME Webcast access featuring simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
At the conclusion of this course, participants will be able to:
- Apply basic, generally-accepted urological practices for superior patient care.
- Demonstrate core knowledge of urology necessary for Part I of the American Board of Urology (ABU) qualifying examination and for the recertification examination.
- Utilize AUA Guidelines for appropriate patient evaluation and management.
Friday, June 1, 2018
|7:30 a.m.||Introduction |
Howard B. Goldman, MD, and Wade J. Sexton, MD
Penile and Urethral Cancer
|Robert G. Uzzo, MD |
Renal and Ureteral Tumors
Robert G. Uzzo, MD
|Michael A. O'Donnell, MD |
|Angela M. Smith, MD |
|12:10 p.m.||Bladder Cancer Questions |
Michael A. O'Donnell, MD and Angela M. Smith, MD
|Howard B. Goldman, MD |
|Claus G. Roehrborn, MD|
|Adam S. Kibel, MD |
|Jay T. Bishoff, MD |
|5:50 p.m.||Meeting Adjourns for the Day|
Saturday, June 2, 2018
|7:00 a.m.||Exam Overview, Test Taking Logistics, and ABU Process|
|Andrew J. Kirsch, MD |
Congenital Urinary Tract Abnormalities
|Armando J. Lorenzo, MD |
Pediatric Urinary Incontinence and Bladder Disorders
|Andrew J. Kirsch, MD|
Disorders of the Genitalia/Scrotum
|Armando J. Lorenzo, MD |
Pediatric Urological Oncology
|10:30 a.m.||Pediatric Review Questions|
Andrew J. Kirsch, MD and Armando J. Lorenzo, MD
|Sara L. Best, MD |
Infection and Inflammation
|Hannah R. Choate, MD |
|Sara L. Best, MD|
|Jay T. Bishoff MD|
Urinary Tract Infection
|3:15 p.m.||Michel Y. Pontari, MD|
|Hannah R. Choate, MD |
|5:45 p.m.||Meeting Adjourns for the Day|
Sunday, June 3, 2018
Female Urology, Urodynamics and Neurology
|Stephen R. Kraus, MD |
|Urodynamics Tracing Review |
Stephen R. Kraus, MD and Howard B. Goldman, MD
|Howard B. Goldman, MD |
|John P. Mulhall, MD|
|Wade J. Sexton, MD|
|Paul J. Turek, MD |
|Brian R. Herts, MD|
|Jay Simhan, MD |
|5:00 p.m.||Course Adjourns|
To hold a reservation, a major credit card number must be provided.
$195 single/double occupancy. Make your reservation online or call 800-233-1234. Reference the AUA Annual Review Course when making your reservation to receive the special group rate.
Cut-off Date: Thursday, May 10, 2018. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.
Check-in: 4 p.m.
Check-out: 11 a.m.
Parking: The Hyatt Regency Austin provides daily self-parking for $24.00 per day. Valet parking is priced at $19.00 for daytime parking with no in-and-out privileges and $32.00 for overnight valet. Prices are subject to change.
Transportation: The Hyatt Regency Austin is located approximately 11 miles/18 minute from Austin-Bergstrom International Airport. Taxi Cost: $20.00 - $27.00 one-way. Travel time is dependent on time of day and traffic conditions. Additional transportation information and directions.
Car Rental: Hertz is pleased to offer special discounted car rental rates to AUA course and meeting attendees. Make your car rental reservation online or call 1-800-654-2240 and mention the AUA discount code CDP# 1953476.
|Sara L. Best, MD||American Urological Association||Meeting Participant or Lecturer||Yes|
|Endourological Society||Meeting Participant or Lecturer||Yes|
|Jay T. Bishoff, MD||Myriad Genetics||Consultant or Advisor, Scientific Study or Trial||Yes|
|Hannah R. Choate, MD||Nothing to disclose||Yes|
|Howard B. Goldman, MD, FACS||allergan||Consultant or Advisor||Yes|
|Nuvectra||Consultant or Advisor||Yes|
|Axonics||Consultant or Advisor||Yes|
|NewUro||Consultant or Advisor||Yes|
|Galvani||Consultant or Advisor||Yes|
|bioness||Scientific Study or Trial||No|
|Cook||Scientific Study or Trial||Yes|
|Medtronic||Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial||Yes|
|Brian Herts, MD||Siemens Healthineers||Scientific Study or Trial||Yes|
|Adam S. Kibel, MD||Profound||Consultant or Advisor||Yes|
|Janssen||Consultant or Advisor||Yes|
|ConfirmMDx||Consultant or Advisor||Yes|
|Pfizer||Consultant or Advisor||Yes|
|Andrew J. Kirsch, MD||Nothing to disclose||Yes|
|Stephen R. Kraus, MD||Laborie||Other : Course Director and Teaching Faculty||Yes|
|Allergan||Consultant or Advisor||Yes|
|Astellas||Consultant or Advisor, Meeting Participant or Lecturer||Yes|
|Gary E. Lemack||Roivant||Consultant or Advisor||Yes|
|Allergan||Consultant or Advisor, Meeting Participant or Lecturer||Yes|
|Armando J. Lorenzo, MD||Yes|
|John P. Mulhall, MD||Association of Peyronie's Disease Advocates (APDA)||Leadership Position||Yes|
|Pfizer||Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial||Yes|
|Michael A. O'Donnell, MD||Viventia||Consultant or Advisor||Yes|
|Fidia Pharmaceuticals||Consultant or Advisor||Yes|
|Abbott Molecular||Scientific Study or Trial||Yes|
|Telesta||Consultant or Advisor||Yes|
|Roche/Genentech||Scientific Study or Trial||Yes|
|Medical Enterprises||Consultant or Advisor, Scientific Study or Trial||Yes|
|Theralase||Consultant or Advisor, Investment Interest||Yes|
|Spectrum Pharmaceuticals||Consultant or Advisor||Yes|
|Photocure||Scientific Study or Trial||No|
|Michel A. Pontari, MD||Lilly||Consultant or Advisor||Yes|
|aquinox||Consultant or Advisor, Scientific Study or Trial||Yes|
|allergan||Consultant or Advisor||Yes|
|Claus G. Roehrborn, MD||Glaxo Smith Kline||Consultant or Advisor, Meeting Participant or Lecturer||Yes|
|Southwest Oncology Group||Scientific Study or Trial||Yes|
|NIDDK||Health Publishing, Scientific Study or Trial||Yes|
|nymox||Consultant or Advisor||Yes|
|Procept Biorobotics||Consultant or Advisor, Scientific Study or Trial||Yes|
|Boston Scientific||Consultant or Advisor||Yes|
|Nxthera||Scientific Study or Trial||No|
|Astellas||Scientific Study or Trial||Yes|
|Neotract||Consultant or Advisor, Scientific Study or Trial||Yes|
|NERI||Consultant or Advisor, Scientific Study or Trial||Yes|
|CALGB Clinical Trial Group||Scientific Study or Trial||Yes|
|Protox||Consultant or Advisor, Scientific Study or Trial||Yes|
|Wade J. Sexton, MD||Nothing to disclose||Yes|
|Jay Simhan, MD||Boston Scientific||Meeting Participant or Lecturer||Yes|
|Coloplast||Meeting Participant or Lecturer||Yes|
|Angela M. Smith, MD||AHRQ||Scientific Study or Trial||Yes|
|PCORI||Scientific Study or Trial||Yes|
|Paul J. Turek, MD||MandalMed||Leadership Position||Yes|
|Medical Board of California||Consultant or Advisor||Yes|
|HealthLoop.com||Consultant or Advisor, Investment Interest||Yes|
|Doximity, Inc||Consultant or Advisor, Investment Interest||Yes|
|Episona, Inc||Consultant or Advisor||Yes|
|Cellarity Biotechnologies, Inc||Leadership Position, Investment Interest, Owner, Product Development||Yes|
|Contraline, Inc||Consultant or Advisor||Yes|
|FutureFamily, Inc||Consultant or Advisor||Yes|
|BioQuiddity, Inc||Consultant or Advisor, Investment Interest||Yes|
|Essential Beginnings, Inc||Leadership Position, Investment Interest, Owner, Product Development||Yes|
|Robert G. Uzzo, MD||Janssen||Meeting Participant or Lecturer||Yes|
|Pfizer||Meeting Participant or Lecturer||Yes|
|Novartis||Scientific Study or Trial||Yes|
|Genentech||Scientific Study or Trial||Yes|
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this live activity for a maximum of 26.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 26.75 AMA PRA Category 1 Credit™
- 26.75 Non-Physician Participation